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Abstract
Background: The aim of this study was to assess the efficacy of choline-stabilized orthosilicic acid (ch-OSA) in
patients with symptomatic knee osteoarthritis (OA).
Methods: In a multicenter, double-blind, placebo-controlled study, 211 patients with knee OA (Kellgren and Lawrence
grade II or III) and moderate to moderately severe pain were randomly allocated to ch-OSA or placebo for 12 weeks.
The primary outcome was the change in the WOMAC pain subscale from baseline to week 12. Secondary outcomes
were changes from baseline to week 12 in WOMAC total, WOMAC stiffness, WOMAC physical function, Subject Global
Assessment and levels of cartilage degradation biomarkers C-terminal telopeptide of collagen type II (CTX-II) and
cartilage oligomeric matrix protein (COMP). Pre-specified subgroup analyses included the effect of gender.
Results: A total of 166 (120 women, 46 men) patients were included in the analysis (87 and 79 in the ch-OSA and
placebo group, respectively). In the total study population, no differences were observed between the two treatment
groups for the different outcomes but significant treatment x gender interactions were found. In men taking ch-OSA, a
significant improvement in WOMAC total, WOMAC stiffness and WOMAC physical function as well as a lower increase
in biomarker levels of cartilage degradation was observed, but not in women. The change in WOMAC pain showed a
similar positive trend in men taking ch-OSA.
Conclusion: After 12 weeks of treatment, no effect was found of ch-OSA in the total study population on clinical
parameters and biomarkers, but a gender interaction was observed. In men, ch-OSA was found effective in reducing
symptoms of knee OA, which was associated with a slight but significant reduction of biomarkers that are related to
cartilage degradation.
Trial registration: The study was registered retrospectively: ISRCTN88583133. Registration date: 2015-10-07.
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Background
Osteoarthritis (OA) is one of the leading causes of func-
tional disability and compromised quality of life in the eld-
erly worldwide [1]. It is a chronic and slowly progressive
disease, with the knee being the most affected weight-
bearing joint [2, 3]. OA is a complex disease of joints, char-
acterised by degradation of articular cartilage, changes of
the subchondral bone and inflammation, leading to pain
and stiffness in the joint [4, 5]. At present, there are no safe
OA therapeutic strategies approved that result in a concur-
rent structural modification and symptom improvement
[6, 7]. The treatment of OA is therefore, besides exercise
and physiotherapy, still mainly based on analgesics, non-
steroidal anti-inflammatory drugs (NSAIDs) and surgical
procedures [8].
Several risk factors for the development of knee OA have
been identified, including age, obesity, injury and genetic
profiles. Sex differences in knee OA incidence and preva-
lence have been reported as well, with females generally at
higher risk [7, 9]. Moreover, the meta-analysis performed by
Srikanth et al. demonstrated that women tend to have more
severe knee OA, particularly after menopausal age [9].
Given the limitations of plain radiography and the high
charges for magnetic resonance imaging (MRI), biochem-
ical markers have gained considerable interest over the
past 15 years [10, 11]. However, in contrast to the well-
established biochemical markers for bone diseases, the
value of biomarkers in OA still needs further elucidation
[12]. To this respect, Bauer et al. proposed the BIPED –
burden of disease, investigative, prognostic, efficacy of
intervention and diagnostic – categories, providing a clas-
sification system for biochemical markers [13]. Among
numerous candidates, C-terminal telopeptide of collagen
type II (CTX-II) and cartilage oligomeric matrix protein
(COMP), which are two markers of cartilage degradation,
have been reported to be the best performing biochemical
markers across all BIPED categories [11].
Choline-stabilized orthosilicic acid (ch-OSA) is a spe-
cific complex of orthosilicic acid and choline that has been
previously demonstrated to stimulate collagen synthesis
which positively affects bone turnover [14] as well as
surface and mechanical properties of the skin [15]. The
choline component of ch-OSA was suggested to contrib-
ute to this effect [14], as it lowers plasma homocysteine
levels [16]. More specifically, hyperhomocysteinemia has
been shown to interfere with collagen cross-linking, lead-
ing to connective tissue pathology [17]. To this respect, it
may be hypothesized that ch-OSA acts on both cartilage
and subchondral bone, consequently rendering it a candi-
date for the treatment of OA. The aim of this study was to
evaluate the symptomatic effects of the oral intake of ch-
OSA on knee OA over a 12-week period. Additionally,
CTX-II and COMP were analysed to assess the influence
of ch-OSA on cartilage degradation.
Methods
A 12-week, international, multicenter, double-blind, ran-
domized, parallel-group, placebo-controlled single-joint
study in outpatients with symptomatic knee OA was per-
formed. Participants were recruited either directly from the
investigation centres (situated in Belgium (ReumaClinic,
Genk and Diagnosecentrum, Lommel; both private hospi-
tals in co-operation with Biomedical Research Institute,
Hasselt University, Hasselt, Belgium and Rheumatology,
Maastricht UMC, Maastricht, The Netherlands), Slovakia
(National Institute of Rheumatic Diseases, Piestany; public
hospital) and Czech Republic (Institute of Rheumatology,
Prague; public hospital) or following pre-screening by
general practitioners (Belgium).
Patients
Potential participants were initially assessed during a screen-
ing visit. The inclusion criteria defined eligible patients as
men and women between 50 and 75 years of age with a
diagnosis of primary knee OA according to the American
College of Rheumatology criteria [18] for at least 12 weeks
prior to randomization i.e. knee pain plus at least three of
the following characteristics: > 50 years, < 30 min of morn-
ing stiffness, crepitus on active motion, bony tenderness,
bony enlargement, no palpable warmth of the synovium.
Additional inclusion criteria comprised a radiographic con-
firmed Kellgren and Lawrence grade II or III (mild to mod-
erate osteophytes and joint space narrowing) in the previous
6 months [19]; a knee OA pain intensity score, assessed by
the question “How would you describe your maximum OA
knee pain when not taking analgesic medications in the 24 h
prior to this visit”, of “moderate (2)” or “moderately severe
(3)” on a 5-point Likert Scale; a Western Ontario and
McMaster University OA Index (WOMAC) physical func-
tion subscale score > 0 on a 100 mm horizontal visual
analogue scale (VAS) [20]. In case both knees were affected,
the knee with the highest pain score was selected as the tar-
get knee. In order to avoid interference with the subject’s
pain perception, the use of paracetamol within a 48 h period
prior to the screening visit was not allowed.
The major exclusion criteria were the following: second-
ary OA of the target knee; morning stiffness of ≥ 30 min; a
swollen or warm joint suspected to be secondary to gout,
pseudo gout or sepsis; significant injury in the target joint
within 6 months before the start of the trial; arthroplasty
and joint surgery of the target knee within 2 years prior to
the start of the study. Additionally, specified previous
medications led to exclusion from the trial.
Following a wash-out period during which the use of
pain medication and OA-related treatments were not
allowed, eligible subjects were scheduled for a baseline
visit. The duration of the wash-out period was at least five
drug half-lives of the corresponding drug, or as described
in the exclusion criteria.
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Design, randomisation and blinding
At the baseline visit, patients were randomly assigned to
take a capsule of either ch-OSA (520 mg ch-OSA beadlets
containing 5 mg of silicon and 100 mg of choline; Bio
Minerals N.V., Belgium) or placebo (520 mg microcrystal-
line cellulose beadlets; Pharmatrans Sanaq AG, Switzerland)
twice daily by oral route for 12 weeks. The treatment
allocation occurred sequentially in a 1:1 ratio using a
randomization list, which was generated by an independent
statistician in R (software version 2.10.1 for Windows; The
R Foundation for Statistical Computing, Vienna, Austria).
More specifically, block randomization was stratified by site,
applying randomly selected block sizes of 2 or 4. The indi-
vidual code was kept in a sealed envelope by the investiga-
tor to be opened only in case of medical emergency.
Patients were assessed by the investigator at baseline
and at 2, 6 and 12 weeks after randomization. At the first
three visits, the study dietary supplement was delivered in
bottles labelled with the subject’s randomization number
(according to the allocation sequence) and the instructions
to take one capsule in the morning and another in the
evening with a glass of water or juice. Blinding among
subjects, investigators and monitors was maintained by
providing identical packaging, appearance, taste and odour
for ch-OSA and placebo capsules, respectively. Treatment
compliance was verified at subsequent visits by counting
the number of unused doses. In this respect, the limit for
an acceptable compliance was set at 75%.
Pain medication and OA-related treatments were not
allowed throughout the trial. However, subjects were
allowed to take up to 2 g of paracetamol per day as rescue
medication in case of intolerable pain, except during a
48 h period before each evaluation.
Assessments and outcome measures
At each visit, allocated patients were requested to complete
a 100 mm horizontal VAS WOMAC questionnaire based
on symptoms in the target knee in the preceding 48 h. This
24-item questionnaire resulted in a total WOMAC score
and three WOMAC subscores, based on the following sub-
scales: pain (5 questions), stiffness (2 questions) and phys-
ical function (17 questions). For each WOMAC score, a 0–
100 mm range was generated by averaging across the re-
spective items, with lower scores indicating better out-
comes. The Subject Global Assessment was evaluated on a
100 mm horizontal VAS as well (0–100 mm range), by
asking the following question: “Considering all the ways
your knee OA affects you, how are you doing today?”.
Finally, fasting serum and second void urine were collected
at the baseline and final visit to assess biochemical markers
of cartilage degradation (urine, serum), baseline serum es-
tradiol and serum silicon concentration. For the collection
of serum, silicon free polypropylene syringes (Sarstedt,
Germany) and needles (Microlance, Becton Dickinson,
Spain) were used as published elsewhere [15]. Aliquots of
both samples were stored at −20 °C until analysis. More
specifically, urinary CTX-II concentrations were deter-
mined using the Urine CartiLaps EIA from IDS (Boldon,
UK). These concentrations were corrected for urinary
creatinine concentrations, which were determined with a
creatinine assay (R&D Systems, Abingdon, UK). Serum
COMP levels were measured using AnaMar Medical’s
(Lund, Sweden) COMP ELISA. Serum Estradiol levels were
measured with Estradiol III electrochemiluminescense im-
munoassay from Roche (Mannheim, Germany). All ana-
lyses were performed according to the manufacturers’
protocols. Serum silicon concentration was measured using
electrothermal atomic absorption spectrometry with inverse
longitudinal Zeeman background correction (AAnalyst 800,
Perkin Elmer, Bodenseewerk, Germany) and the analytical
features (temperature program, matrix modifier, sample
preparation method) were published elsewhere [15].
The primary outcome measure was the change in the
WOMAC pain subscale from baseline to week 12. Second-
ary outcome measures included the changes from baseline
to 12 weeks in the total WOMAC score, the WOMAC stiff-
ness subscale, the WOMAC physical function subscale, the
Subject Global Assessment and CTX-II and COMP levels.
Statistical analysis
The sample size calculation estimated that a group size of
100 subjects was necessary to ensure at least 80% power to
detect differences of 16% between the ch-OSA and placebo
group with respect to pain and physical function (quantified
according to the WOMAC pain and function subscale, as-
suming a relative standard deviation of 40% (based on data
of 13 studies; Additional file 2: Table S2)), considering a
dropout rate of 10% and a 0.05 two-sided significance level.
Statistical analyses were performed using the per-
protocol population, defined as all randomized patients
meeting the inclusion criteria, who completed the trial
and who did not have major protocol violations. Results
are presented as mean ± standard deviation (SD).
For WOMAC total, WOMAC subscales and Subject
Global Assessment scores, a repeated measures (RM) uni-
variate analysis of covariance (ANCOVA) model was ap-
plied in which the baseline value was treated as a covariate
while treatment and gender were treated as fixed factors.
Between and within treatment differences were assessed
and the models also included interaction terms between
treatment and gender. Differences in serum silicon and
biomarker values (baseline versus final visit) were analysed
between and within treatments using RM analysis of vari-
ance (ANOVA), albeit after removal of outliers. These out-
liers were identified using the median absolute deviation
and a critical value of 4.5 [21]. In case of a significant inter-
action between time and treatment, post hoc t-tests with
Bonferroni correction were performed.
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Additionally, as specified in the study protocol, sub-
group analyses by gender were performed for all outcome
measures. Due to the smaller group sizes, non-parametric
tests were used. More specifically, differences between
treatment groups were analysed with Mann-Whitney U,
whereas differences within treatment groups were ana-
lysed using Friedman’s test with post hoc Bonferroni-
corrected Wilcoxon signed-ranks. Correlation of serum
silicon with clinical parameters was analysed in subgroups
with the Spearman rank correlation test.
Significance levels were set at P < 0.05 (two-sided), ex-
cept for interaction tests (P < 0.10) [22]. All statistical
analyses were performed using SPSS software (version
21.0 for Windows, IBM Corp., Armonk, NY, USA).
Results
Patients
Between June 2010 and April 2012, a total of 211 eli-
gible subjects were randomized and allocated to receive
ch-OSA (n = 106) or a placebo (n = 105). As demonstrated
in Fig. 1, 166 patients were ultimately included in the
per-protocol analysis. Demographic variables, baseline
disease characteristics and baseline outcome measures
were similar in both groups (Table 1). Mean age of
the randomized patients was 61.9 ± 7.1 years with a
majority of postmenopausal women. The mean baseline
serum level of estradiol was significantly (P < 0.0005)
lower in women compared to men (Table 1). Baseline
CTX-II levels showed a higher trend (P = 0.1) in women
compared to men (Table 1).
Compliance and safety
Compliance throughout the study was excellent as 98%
of the patients reached the minimum compliance of
75%. Overall, the mean compliance was 106 ± 12% in the
per-protocol population and > 100% both in men and
women. No adverse events related to the treatment were
reported in either treatment group.
Fig. 1 Flow diagram of study enrolment, allocation, follow-up and analysis
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Efficacy
The primary and secondary outcome measures are
shown in Table 2, along with the absolute values of the
assessed clinical outcome measures at the different visits.
After 12 weeks of treatment, the change from baseline
in silicon serum levels was significantly higher in the ch-
OSA group compared to the placebo group (Table 2).
The statistical analyses demonstrated no significant
differences between the two treatment groups with re-
spect to the primary and secondary outcome measures.
Nevertheless, significant treatment x gender interactions
were found for all clinical outcomes (ANCOVA).
Subsequently, pre-specified subgroup analyses by gender
were performed. Table 3 provides an overview of the
assessed parameters in men and women in the placebo
and ch-OSA group, respectively. There was a superior ef-
fect of ch-OSA in men after 12 weeks of treatment as the
mean changes from baseline in WOMAC total, WOMAC
stiffness and WOMAC physical function were significantly
higher with ch-OSA compared to placebo (Fig. 2). The
corresponding mean differences (95% CI) between placebo
and ch-OSA in men were the following: WOMAC total
11.0 mm (0.1 to 21.9), WOMAC stiffness 16.5 mm (3.0 to
30.0) and WOMAC physical function 10.6 mm (−0.5 to
21.6). A similar, yet non-significant trend was observed for
WOMAC pain and Subject Global Assessment: 10.2 mm
(−1.7 to 22.1) and 8.4 mm (−5.5 to 22.3), respectively. As
shown in Fig. 3, increases in biomarkers of cartilage
degradation (CTX-II and COMP) were significantly lower
after 12 weeks in the male ch-OSA group, resulting in the
following mean differences (95% CI) between placebo and
ch-OSA: CTX-II 102.0 ng/mmol (12.6 to 191.4) (Fig. 3a)
and COMP 2.1 U/L (0.3 to 3.9) (Fig. 3b). The statistical
analysis of the female subgroups, on the other hand,
demonstrated no significant treatment differences (data
not shown). Similar as in the total study population, the
change from baseline in silicon serum levels was signifi-
cantly higher in the ch-OSA group compared to the pla-
cebo group for both women and men. The following
observed mean differences (95% CI) between placebo and
ch-OSA were observed: men, 26.1 μg/L (3.15 to 49.4) and
women, 46.0 μg/L (27.0 to 65.0). No significant correla-
tions were found between clinical parameters and serum
silicon in neither women nor men (data not shown).
Discussion
This is the first clinical study to evaluate the symptom re-
lief effect of ch-OSA in patients with knee OA. Although
the intake of the dietary supplement for 12 weeks failed to
show a statistically significant benefit over placebo regard-
ing the clinical outcome scores and biomarker values in
the per-protocol population, pre-specified subgroup ana-
lyses demonstrated a significant effect of ch-OSA in men.
Accordingly, WOMAC total, stiffness and physical
function scores were significantly reduced in men taking
ch-OSA compared to men in the placebo group. While
Table 1 Baseline characteristics of the study population by treatment group and gender
Characteristic Placebo (n = 79) ch-OSA (n = 87) Male (n = 46) Female (n = 120)
Age (years) 62.2 ± 7.7 61.7 ± 6.5 61.0 ± 7.2 62.3 ± 7.0
Women 55 (69.6) 65 (74.7) 0 120 (100)
Body mass index (kg/m2) 29.5 ± 5.2 29.5 ± 5.4 29.1 ± 4.7 29.6 ± 5.6
Menopausal Status 1 pre (1.5) 1 pre (1.8) - 2 pre (1.7)
0 peri (1.5) 1 peri 1 peri (0.8)
54 post (98.2) 63 post (96.9) 117 post (97.5)
Kellgren and Lawrence grade II 48 (60.8) 59 (67.8) 26 (56.5) 81 (67.5)
Kellgren and Lawrence grade III 31 (39.2) 28 (32.2) 20 (43.5) 39 (32.5)
Likert pain score 2 38 (48.1) 32 (36.8) 19 (41.3) 51 (42.5)
Likert pain score 3 41 (51.9) 55 (63.2) 27 (58.7) 69 (57.5)
WOMAC Total (/100 mm) 43.1 ± 20.3 40.9 ± 19.4 42.2 ± 21.5 41.9 ± 19.2
WOMAC Pain (/100 mm) 41.2 ± 20.3 38.2 ± 19.8 41.9 ± 20.9 38.7 ± 19.7
WOMAC Stiffness (/100 mm) 45.3 ± 24.6 44.0 ± 23.5 44.9 ± 23.4 44.5 ± 24.3
WOMAC Function (/100 mm) 43.4 ± 21.2 41.4 ± 19.8 42.0 ± 22.5 42.5 ± 19.7
Subject Global Assessment (/100 mm) 49.4 ± 21.8 50.1 ± 18.2 51.3 ± 22.4 49.2 ± 19.0
CTX-II/Creatinine (ng/mmol) 413.1 ± 189.6 430.4 ± 212.7 378.5 ± 162.8 441.0 ± 213.9
COMP (U/L) 10.8 ± 2.8 10.7 ± 2.8 11.0 ± 2.8 10.6 ± 2.8
Estradiol (ng/L) - - 35.5 ± 31.0 22.0 ± 36.2 a
Data expressed as mean ± SD or n (%);-: not applicable; a significant difference between groups (men versus women); Number of patients without outliers for
CTX-II: Placebo (n = 66), ch-OSA (n = 68); Number of patients without outliers for COMP: Placebo (n = 74), ch-OSA (n = 80)
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levels of cartilage degradation related biomarkers in-
creased over 12 weeks in men in the placebo group and in
women in both groups, these levels were significantly
lower in the male ch-OSA group at the final visit. More
specifically, the increase in CTX-II was less pronounced
and COMP levels remained unchanged. The former sug-
gests that ch-OSA can slow the ongoing progression of
cartilage degradation in men.
The management of knee OA remains a major challenge.
The key objective is to cease or delay disease progression
by controlling cartilage degradation, inflammation and
changes of subchondral bone. Nevertheless, most published
recommendations primarily aim to control OA symptoms
since safe and effective disease-modifying OA drugs
(DMOADs) are currently lacking [23–26]. NSAIDs, for in-
stance, are still among the most commonly used medicines
to relieve OA pain, regardless of their well-known side-
effects in prolonged therapy [24, 27]. The rationale for
studying the effectiveness of ch-OSA in knee OA was con-
sequently based on its previously demonstrated effect on
collagen synthesis and its safety in long-term use [14, 15].
The components of ch-OSA, choline and orthosilicic acid
(OSA), have both been mentioned with respect to collagen
metabolism. Firstly, choline lowers plasma homocysteine
levels through its precursor-function in the biochemical
conversion of homocysteine to methionine [16]. This re-
duction positively affects collagen cross-linking, since
homocysteine has been shown to interfere with post-
translational modifications of collagen through direct and
indirect inhibition of lysyl oxidase as well as through down
regulation of other genes involved in collagen cross-linking
[28]. Indeed, Zhang et al. recently reported elevated serum
homocysteine levels in patients with severe OA compared
to those with mild OA or healthy controls [29]. Secondly,
although the exact role of silicon in bone and connective
tissue health remains unclear, its involvement in collagen
synthesis and/or stabilisation was recently put forward by
Jugdaohsingh et al. [30]. In the present study, the lack of
correlation between the change in serum silicon and clin-
ical parameters in men taking ch-OSA, suggests that the ef-
fect of ch-OSA cannot be explained as an effect of silicon
only. ch-OSA was previously shown to have a positive ef-
fect on markers of bone formation, with a significant in-
crease of procollagen type I N-terminal propeptide (PINP)
in osteopenic women following a supplementation period
of 12 months [14]. In an animal model for postmenopausal
osteoporosis, it was demonstrated that ch-OSA partially
prevented femoral bone loss [31].
The former supports the hypothesis of a possible effect
of ch-OSA on collagen in both cartilage and subchon-
dral bone and consequently on knee OA, particularly in
view of increasing evidence of a close interrelationship
between subchondral bone and articular cartilage [32,
33]. A positive effect of ch-OSA was indeed confirmed
in the present study, already after 12 weeks of treatment,
yet only in men. Several hypotheses can be suggested
with respect to this gender difference. In general, women
report more pain and disability from knee OA [34, 35].
The perception of pain, however, has been demonstrated
to depend on the estrogen state. In fact, a low estrogen
state was found to be related to hyperalgesia [36].
Consequently, the possibility that the enhanced pain
Table 3 Gender-specific subgroups: Overview of the absolute clinical outcome scores and biomarker values at baseline, week 2,
week 6 and week 12 in the placebo and choline-stabilized orthosilicic acid (ch-OSA) group
Placebo (n = 79)



















42.0 ± 22.4 37.5a ± 26.2 34.1a ± 24.3 34.7 ± 30.7 43.6 ± 19.6 39.8 ± 19.0 32.1a, b ± 19.9 31.2 a ± 20.5
WOMAC pain score
(/100 mm)
42.5 ± 22.7 35.1a ± 24.5 32.6a ± 24.0 33.0 ± 31.2 40.6 ± 19.4 37.2 ± 19.7 29.3a, b ± 19.8 28.2 a ± 20.1
WOMAC stiffness score
(/100 mm)
43.8 ± 25.3 40.0 ± 27.3 33.5 ± 26.4 38.2 ± 29.6 45.9 ± 24.5 39.5a ± 23.2 32.4a, b ± 22.2 32.2 a ± 22.8
WOMAC function score
(/100 mm)
41.7 ± 23.3 37.9 ± 27.3 34.6 ± 25.2 34.9 ± 31.0 45.9 ± 24.5 39.5 ± 23.2 32.4a, b ± 22.2 32.2 a ± 22.8
Subject Global Assessment
(/100 mm)
51.1 ± 26.0 41.7 ± 22.4 33.3 a ± 23.4 33.8a ± 24.3 48.6 ± 19.9 37.9a ± 18.8 33.5a, b ± 19.7 32.0 a ± 22.2
CTX-II/Creatinine (ng/mmol) 389.8 ± 178.0 - - 565.2a ± 267.8 425.6 ± 196.5 - - 508.1a ± 259.5
COMP (U/L) 11.1 ± 3.0 - - 13.0a ± 3.6 10.6 ± 2.7 - - 10.6 ± 3.2
Silicon (μg/L) 54.4 ± 28.1 - - 59.2 ± 36.0 49.5 ± 35.6 67.8 a ± 44.4
asignificant difference from baseline within the group; b significant difference from week 2 within the group; c significant difference between groups (placebo
versus ch-OSA); -: not applicable; Number of patients without outliers for CTX-II: placebo males (n = 23), placebo females (n = 43), ch-OSA males (n = 18), ch-OSA
females (n = 50); Number of patients without outliers for COMP: placebo males (n = 22), placebo females (n = 52), ch-OSA males (n = 21), ch-OSA females (n = 59);
Number of patients without outliers for Silicon: placebo males (n = 19), placebo females (n = 50), ch-OSA males (n = 19), ch-OSA females (n = 56)
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perception masked the effect of ch-OSA in women in
the present study cannot be ruled out given the predom-
inance of postmenopausal women (98%) with low en-
dogenous estrogen levels, of which only 7% was on
hormone replacement therapy (HRT), a contraceptive, a
selective estrogen receptor modulator (SERM) or phy-
toestrogens. In fact, the mean serum estradiol level of
women in the present study was significantly lower com-
pared to that of the male study population.
Besides the fact that postmenopausal women have a
different pain perception than man, it has also been con-
firmed that the severity of knee OA is higher in women
as well, and principally in postmenopausal women [9, 37].
Accordingly, urinary CTX-II levels were found to be
significantly higher in postmenopausal women than in
men [38]. The latter is in correspondence with the
trend towards higher baseline CTX-II concentrations
observed in – predominantly postmenopausal – women
in the present study. Again, decreased estrogen levels
might be of importance. Several in vitro, in vivo, genetic
and clinical studies indeed designate a potential protective
role for estrogens against the development of OA, given
the various actions of estrogen on articular tissues [39].
Additionally, considerable experimental models indicate
that estrogen deficiency-related increases in bone turnover
contribute to the progression of OA [40, 41]. Therefore, in
view of the more severe OA forms in women, it can be
suggested that the 12-week supplementation period could
have been insufficient to result in a clinical benefit.
Given the apparent extensive involvement of estrogen de-
ficiency in the development and progression of knee OA,
the use of HRTs or SERMs in women seems plausible.
Nevertheless, it has been concluded that the health risks of
HRTs may outweigh the potential benefits and that HRTs
Fig. 2 Mean change (± SD) from baseline to week 12 in WOMAC total, WOMAC pain, WOMAC stiffness, WOMAC physical function and Subject
Global Assessment in men. P values refer to differences between placebo and choline-stabilized orthosilicic acid (ch-OSA)
Table 3 Gender-specific subgroups: Overview of the absolute clinical outcome scores and biomarker values at baseline, week 2,
week 6 and week 12 in the placebo and choline-stabilized orthosilicic acid (ch-OSA) group (Continued)
ch-OSA (n = 87)



















42.5 ± 20.9 36.1a ± 22.1 26.8a ± 22.8 24.2a ± 21.3 40.4 ± 19.0 37.7 ± 20.7 30.4a, b ± 21.2 31.1a ± 23.4
WOMAC pain score
(/100 mm)
41.3 ± 19.3 32.2a ± 20.0 24.3a ± 21.5 21.6a ± 19.6 37.1 ± 20.0 35.5 ± 21.9 28.8a, b ± 22.0 27.6a ± 22.9
WOMAC stiffness score
(/100 mm)
46.2 ± 21.8 37.2a ± 25.3 28.8a ± 23.8 24.1a ± 23.4 43.3 ± 24.1 39.4 ± 22.5 31.1a, b ± 22.6 32.0a ± 25.3
WOMAC function score
(/100 mm)
42.4 ± 22.2 27.1 ± 22.9 27.3a ± 23.5 25.0a ± 22.3 43.3 ± 24.1 39.4 ± 22.5 31.1a, b ± 22.6 32.0a ± 25.3
Subject Global Assessment
(/100 mm)
51.5 ± 18.3 36.6a ± 20.9 24.6a, b ± 20.8 25.8 a ± 23.7 49.6 ± 18.3 42.7a ± 22.8 36.5a, b ± 24.9 34.2a ± 24.6
CTX-II/Creatinine (ng/mmol) 364.0 ± 144.7 - - 437.4a ± 171.8 454.3 ± 229.0 - - 568.3a ± 282.6
COMP (U/L) 10.9 ± 2.7 - - 10.6 ± 2.7 10.6 ± 2.9 - - 11.3a ± 2.8
Silicon (μg/L) 68.4 ± 38.0 - - 99.3a, c ± 42.7 57.0 ± 35.3 - - 121.3a, c ± 59.1
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and SERMs should not be recommended as first-line treat-
ments for OA [42, 43]. Several other pharmacological ther-
apies have been studied with respect to knee OA, including
symptomatic slow-acting drugs for OA (SYSADOAs) like
glucosamine sulphate, chondroitin sulphate, hyaluronic acid
and diacerein. Due to the frequently inconsistent conclu-
sions of these studies, the appropriateness of the former
therapies has been recently designated as uncertain [26].
Furthermore, therapeutic approaches that target subchon-
dral bone resorption and/or formation have gained atten-
tion [32, 43]. Bisphosphonates, strontium ranelate and
calcitonin have been studied in this context, yet none of
these treatments has been approved as a DMOAD since
evidence of concomitant structural and symptomatic effects
is still pending [6, 26]. Additionally, safety issues are of im-
portance, such as the risk of cardiovascular events associ-
ated with strontium ranelate [44]. The safety of ch-OSA in
prolonged therapy, on the other hand, has been previously
demonstrated [45].
Although the relevance of biochemical markers in OA
has not yet been proven to be of definite clinical import-
ance, Lotz et al. described their value as secondary out-
comes [12]. More specifically, effects on biomarkers can
support the primary outcome and provide evidence of
Fig. 3 Mean change (± SD) from baseline to week 12 in CTX-II (a) and COMP (b) levels in men. P values refer to differences between placebo
and choline-stabilized orthosilicic acid (ch-OSA)
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pharmacodynamics and mechanisms of action of OA
drugs. This is indeed valid in the present study, given that
the trend observed for the primary outcome (WOMAC
pain) in ch-OSA-treated men was associated with signifi-
cantly lower biomarker levels, the latter referring to de-
creased cartilage degradation.
The present study has a number of limitations. Firstly,
the evaluation of the magnitude of pain changes is am-
biguous. This is related to the relatively high placebo
effect – which is however common in OA trials – on
the one hand, and to the complicated interpretation of
changes evaluated as means rather than individual im-
provements, on the other hand [46]. Furthermore, the
dropout rate was higher than assumed in the sample size
calculation (18% in contrast to the postulated 10%),
which negatively affected the statistical power in the
subgroup analyses, particularly in the male subgroups.
In conclusion, this randomized, placebo-controlled
trial provided a first indication of a potential benefit of
ch-OSA in the treatment of knee OA in men, particu-
larly in view of the need for a safe long-term treatment.
Future research is however needed to further elucidate
the observed effects and gender difference since no
benefit was found in women. Considering the hypothesis
that the 12-week supplementation period may have been
insufficient in women, an extension of the treatment
duration to at least 6 months would be valuable [47].
Additionally, the inclusion of younger, premenopausal
women could, at least in part, contribute to the clarifica-
tion of the role of estrogen in OA. The potential
disease-modifying effects of ch-OSA at the level of the
knee, on the other hand, could be evaluated after a
prolonged treatment period using reliable and sensi-
tive imaging technologies, such as MRI or high-
resolution peripheral quantitative computed tomog-
raphy (HRpQCT) [43, 48]. Determination of biochem-
ical markers of bone metabolism could also extend
the knowledge on the mechanisms of action of ch-
OSA. Finally, application of the former research sug-
gestions would also contribute to the identification of
different subgroups. These subgroups could then be
subjected to separate statistical analyses, which could
provide evidence for the further assessment of ch-OSA’s
potentials in view of individualized targeted treatments for
knee OA.
Conclusions
Choline-stabilized orthosilicic acid did not improve
symptoms of knee osteoarthritis in the total study popu-
lation but a gender effect was observed. A symptomatic
improvement was found in men but not in women, after
12 weeks of supplementation, which was associated with
a slight but significant reduction of biomarkers which
are related to cartilage degradation. In view of the need
for a safe long-term therapy for the treatment of knee
osteoarthritis, this study provided first evidence on the
potential benefit of choline-stabilized orthosilicic acid.
Future research is however needed to further elucidate
the observed effects and gender difference. Considering
the hypothesis that the 12-week supplementation period
may have been insufficient in women, an extension of
the treatment duration to at least 6 months would be
valuable.
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